WWFHTX is a grassroots initiative that unites health consumers, biopharmaceutical company employees vendors, suppliers, academic and community partners.
The prescription drug supply chain, including #PBMs, is now making more money off of those #medicines than the #biopharma companies that developed them. https://t.co/rOP8XYNOvY @txhbi From: Berkeley Research Group #BRG
Post election there’s bipartisan support to break up the “Big 3” #HealthInsurance - #PBM behemoths that control 80%+ of U.S. prescriptions.
https://t.co/e75hBvFZEk
Average mo. #healthinsurance premium costs almost as much as monthly mortgage payment. But premiums are only part of the story. More from @IWCoalition. @TXDisabilities https://t.co/675Ue1ecEQ
.@USDOL rule to require #PBMs to disclose information about their fees & compensation from drugmakers, pharmacies, consultants and more – which could help reveal potential conflicts of interest. @txhbi https://t.co/zpcupyQgNv
Independent oncology practices bring firsthand perspective on how #PBMs’ control of #cancer medications affects #PatientAccess and care. https://t.co/aeD09CJxmh
Report reveals how private #healthinsurance companies are shortchanging rural hospitals, even as UnitedHealth Group earned enough in just 3 months to keep every at-risk hospital open for a year. @StopAfib https://t.co/nkt57V2SYa
@IAmBiotech CEO says the U.S. needs policies, initiatives that maintain and advance our global leadership in #biotech, particularly as we compete with China. @txhbi https://t.co/XXdtNfSgAu
New @USDOL regulation will force middlemen #PBMs to reveal their many sources of revenue and the tactics used to gain that revenue. @IAFAccess https://t.co/yvePiVZ9yz
Some 70% of Americans support antitrust enforcement to break up large #healthinsurance companies. By a 20-to-1 margin, voters want to block insurers from buying #healthcare providers. https://t.co/rigKp8fzbP
Per @sallypipes, broad restrictions like #COINSAct could give China #biotech firms an advantage while denying U.S. patients access to new treatments. https://t.co/0Ydk1fvAhj
New report calls for stronger #HealthInsurance accountability by, among other things, stopping AI from making #healthcare altering decisions. @TXDisabilities https://t.co/QxY6KFc8ET
.@ambiosecurity paper warns sweeping restrictions on investment, partnerships & supply chains intended to slow China’s rise could undermine America’s own #biotech capacity & national security. @txhbi https://t.co/NeHUQ5gdTE
@USTreasury’s regulations implementing the #COINSAct could cripple the dynamic ecosystem that fuels U.S. #biomedical leadership, leaving patients paying the price, per @ProtecTaxpayers. https://t.co/hCU8PYRQvl
“Due to Congress’ lack of clear expectations and guidelines, the #340B program has become an opaque revenue stream for hospitals and pharmacies, with little accountability to ensure savings benefit patients and taxpayers.” @TCCRI https://t.co/aQAmI5dGB6
Re: the #IRA: “We know from the small molecule #pillpenalty that #cancer and diseases of the brain are significantly disadvantaged and have seen measurably less investment as a result.” https://t.co/Uzmg6xb3N6
.@CMSGov proposes rule to limit #PBMs to flat service fees that can’t be based on factors like the price of a drug, the rebates it generates or its placement on a formulary. @BioNorthTX https://t.co/DWis2vPNEx